Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research issued their Q1 2027 earnings estimates for Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das anticipates that the biopharmaceutical company will earn ($0.23) per share for the quarter. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' FY2027 earnings at ($1.02) EPS and FY2027 earnings at ($1.02) EPS.
Several other analysts have also commented on NKTR. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday, March 13th. B. Riley assumed coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price on the stock. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target for the company in a report on Friday, March 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research note on Thursday, March 13th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $4.92.
Check Out Our Latest Analysis on NKTR
Nektar Therapeutics Price Performance
Shares of Nektar Therapeutics stock traded up $0.03 during trading on Friday, hitting $0.52. 1,465,845 shares of the company's stock traded hands, compared to its average volume of 1,863,483. Nektar Therapeutics has a twelve month low of $0.43 and a twelve month high of $1.93. The company has a market cap of $97.33 million, a PE ratio of -0.63 and a beta of 0.69. The firm's fifty day moving average price is $0.80 and its 200 day moving average price is $1.01.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.33. The company had revenue of $29.18 million for the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.
Institutional Trading of Nektar Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC lifted its holdings in Nektar Therapeutics by 56.3% during the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 9,958 shares in the last quarter. Harvest Investment Services LLC acquired a new position in shares of Nektar Therapeutics during the fourth quarter valued at $27,000. Intech Investment Management LLC bought a new position in Nektar Therapeutics in the third quarter valued at about $41,000. US Asset Management LLC bought a new position in Nektar Therapeutics in the fourth quarter valued at about $31,000. Finally, XTX Topco Ltd acquired a new stake in Nektar Therapeutics in the third quarter worth about $46,000. Institutional investors and hedge funds own 75.88% of the company's stock.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Articles
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
